Please use this identifier to cite or link to this item:
Title: Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Austin Authors: Ohtsu, Atsushi;Ajani, Jaffer A;Bai, Yu-Xian;Bang, Yung-Jue;Chung, Hyun-Cheol;Pan, Hong-Ming;Sahmoud, Tarek;Shen, Lin;Yeh, Kun-Huei;Chin, Keisho;Muro, Kei;Kim, Yeul Hong;Ferry, David;Tebbutt, Niall C ;Al-Batran, Salah-Eddin;Smith, Heind;Costantini, Chiara;Rizvi, Syed;Lebwohl, David;Van Cutsem, Eric
Affiliation: Salah-Eddin Al-Batran, Institute for Clinical Oncology Research, Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany
Chiara Costantini, Novartis Pharma AG, Basel, Switzerland
Eric Van Cutsem, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Atsushi Ohtsu, National Cancer Center Hospital East, Kashiwa; Keisho Chin, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan; Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX; Tarek Sahmoud, Heind Smith, Syed Rizvi, David Lebwohl, Novartis Pharmaceuticals, Florham Park, NJ; Yu-Xian Bai, Tumor Hospital of Harbin Medical University, Harbin; Hong-Ming Pan, Sir Run Run Shaw Hospital, Zhejiang; Lin Shen, Peking University Cancer Hospital, Beijing, People's Republic of China; Yung-Jue Bang, Seoul National University College of Medicine; Hyun-Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yeul Hong Kim, Korea University Anam Hospital, Seoul, South Korea; Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; David Ferry, New Cross Hospital, Wolverhampton, United Kingdom; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 16-Sep-2013
Publication information: Journal of Clinical Oncology 2013; 31(31): 3935-43
Abstract: The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer.Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were randomly assigned to everolimus 10 mg/d (assignment schedule: 2:1) or matching placebo, both given with BSC. Randomization was stratified by previous chemotherapy lines (one v two) and region (Asia v rest of the world [ROW]). Treatment continued until disease progression or intolerable toxicity. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), overall response rate, and safety.Six hundred fifty-six patients (median age, 62.0 years; 73.6% male) were enrolled. Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124). Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78). Common grade 3/4 adverse events included anemia, decreased appetite, and fatigue. The safety profile was similar in patients enrolled in Asia versus ROW.Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy. The safety profile observed for everolimus was consistent with that observed for everolimus in other cancers.
Gov't Doc #: 24043745
DOI: 10.1200/JCO.2012.48.3552
Journal: Journal of Clinical Oncology
Type: Journal Article
Subjects: Adenocarcinoma.drug therapy.mortality
Aged, 80 and over
Disease-Free Survival
Double-Blind Method
Immunosuppressive Agents.therapeutic use
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local.drug therapy
Proportional Hazards Models
Sirolimus.analogs & derivatives.therapeutic use
Stomach Neoplasms.drug therapy.mortality
Young Adult
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.